Update on 76471 RE: 76418 FDA Freedom of Information Act Appeal: FOIA 2024-5142
The information and concerns you shared in your messages were forwarded to the appropriate staff within FDA’s Center for Biologics Evaluation and Research (CBER).
More news from FDA
Following on from yesterday’s post below:
I received an email this morning as so:
“Dear Hedley:
Thank you for your follow-up message to the U.S. Food and Drug Administration (FDA). Your email has been forwarded to FDA’s Center for Biologics Evaluation and Research (CBER) for response. One of seven centers within the FDA, CBER is responsible for the regulation of many biologically-derived products, including blood intended for transfusion, blood components and derivatives, vaccines, allergenic products, tissue, and cell and gene therapy products.
The information and concerns you shared in your messages were forwarded to the appropriate staff within FDA’s Center for Biologics Evaluation and Research (CBER). Should there be the need for follow up on the information you provided, someone may contact you to obtain further information.
Please kn…